BCG unresponsive high-risk non-muscle invasive (Ta/T1/CIS) bladder cancer (TURBT)

Registration
Stratify by CIS disease component at registration:
Present vs. Absent

Atezolizumab for 17 cycles (51 weeks)*

Follow-up
Maximum 5 years from registration

* Cystoscopy and cytology performed as specified in the study calendar (see Section 9.0). Mandatory biopsy at Week 25 for patients with any CIS component.